Skip to content
Streptozocin
Zanosar (streptozocin) is a small molecule pharmaceutical. Streptozocin was first approved as Zanosar on 1982-05-07. It is used to treat colorectal neoplasms, hodgkin disease, and islet cell carcinoma in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
hemic and lymphatic diseasesD006425
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Zanosar
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Streptozocin
Tradename
Company
Number
Date
Products
ZANOSARTevaN-050577 RX1982-05-07
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zanosarNew Drug Application2023-04-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colorectal neoplasmsD015179
hodgkin diseaseD006689C81
islet cell carcinomaD018273C25.4
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01A: Alkylating agents
L01AD: Nitrosoureas, antineoplastic alkylating agents
L01AD04: Streptozocin
HCPCS
Code
Description
J9320
Injection, streptozocin, 1 gram
Clinical
Clinical Trials
133 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201544291326124
Acquired immunodeficiency syndromeD000163EFO_0000765B203418
HivD006678O98.7145
HepatitisD006505HP_0012115K75.911
ExanthemaD005076R2111
Cardiovascular diseasesD002318EFO_0000319I9811
Hiv-associated lipodystrophy syndromeD039682EFO_100134811
LipodystrophyD008060E88.111
Aids-related opportunistic infectionsD01708811
Hemophilia aD006467EFO_0007267D6611
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aids-associated nephropathyD016263EFO_000731311
Lactic acidosisD000140EFO_1000036E87.20111
Aids dementia complexD015526EFO_000260811
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TuberculosisD014376EFO_0000774A15-A1911
PregnancyD011247EFO_0002950Z33.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cryptococcal meningitisD016919EFO_0007228B45.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSTREPTOZOCIN
INNstreptozocin
Description
Streptozocin is an N-nitrosourea that is an antibiotic produced by Streptomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. It has a role as an antineoplastic agent, an antimicrobial agent, a DNA synthesis inhibitor and a metabolite. It is a N-acylglucosamine and a member of N-nitrosoureas.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
Identifiers
PDB
CAS-ID18883-66-4
RxCUI
ChEMBL IDCHEMBL1651906
ChEBI ID
PubChem CID29327
DrugBankDB00428
UNII ID5W494URQ81 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,894 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zanosar
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,426 adverse events reported
View more details